Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2026-03-26 00:00:00 ET · period of report 2026-03-24 · accession 0001816838-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-26 | 2026-03-25 | ACAD | Owen Adams Catherine | CEO, Dir | S - Sale+OE | $21.47 | -11.6K | 14.8K | -44% | -$249.9K |
| D | 2026-03-26 | 2026-03-24 | ACAD | Owen Adams Catherine | CEO, Dir | M - OptEx | $0.00 | +23.5K | 26.4K | +801% | $0 |
| D | 2026-03-26 | 2026-03-24 | ACAD | Owen Adams Catherine | CEO, Dir | M - OptEx | $0.00 | -23.5K | 70.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-25 | S | D | 11,641 | $21.47 | 14,803 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-24 | M | A | 23,509 | $0.00 | 26,444 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 2,935 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan. |
| 3 | Derivative | Restricted Stock Units | 2026-03-24 | M | D | 23,509 | $0.00 | 70,530 | D | — · — to — | 23,509 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units vest in four equal annual installments beginning March 24, 2026. |